Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest News
tonies introduces Toniebox Lite: growing the globally loved audio ecosystem for children
Alonso says 'great signing' Rogers can rejuvenate Chelsea
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For
Littelfuse (LFUS) Pulled Back This Month, Is The 18% Discount Justified?
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.astrazeneca.com |
| Audit Risk | 3 |
| Board Risk | 8 |
| Overall Risk | 8 |
| Market Cap | 196.50B |
| Trailing P/E | 25.39 |
| Forward P/E | 14.66 |
| Dividend Rate | 2.36 |
| Dividend Yield | 1.86% |
| Trailing Annual Div. Rate | 3.2 |
| Trailing Annual Div. Yield | 0.03% |
| Trailing EPS | 4.99 |
| Forward EPS | 8.64 |
| Book Value | 22.85 |
| Price-to-Book | 554.55 |
| Enterprise-to-Revenue | 3.68 |
| Enterprise-to-EBITDA | 11.12 |
| Ex-Dividend Date | 02/19/2026 |
| Earnings Date | 07/27/2026 |
| Earnings Call Date | 07/27/2026 |
| Earnings Average | 2.47 |
| Earnings Low | 2.39 |
| Earnings High | 2.58 |
| Revenue Average | 15.43B |
| Revenue Low | 15.19B |
| Revenue High | 15.70B |